Independent reference. Not affiliated with, endorsed by, or speaking for the U.S. Food and Drug Administration.
FDA Medication Tracker

← All approvals · Other · 2025

Nereus (tradipitant)

The FDA approved Nereus (tradipitant) on December 30, 2025 to treat vomiting associated with motion.
Brand name
Nereus
Generic name
tradipitant
FDA approval date
December 30, 2025
Approved use (FDA wording)
To treat vomiting associated with motion
Company
Vanda Pharms Inc.
Application
NDA220152
Dosage form / route
CAPSULE · ORAL
Boxed warning on label
Not listed
Category on this site
Other

Indications and usage, from the FDA label

NEREUS is indicated for the prevention of vomiting induced by motion in adults. NEREUS is a substance P/neurokinin 1 (NK1) receptor antagonist indicated for the prevention of vomiting induced by motion in adults. ( 1 )

Official sources

Facts only. This site lists what the FDA has approved and what the FDA says each drug is approved for, quoted or closely paraphrased from FDA and openFDA records. It gives no medical advice, no dosing, and no comparisons, and it says nothing about whether a drug is right for anyone. Talk to a licensed clinician about any medication. Records can lag or contain errors; the FDA's own pages are authoritative.